Answers are grounded in this paper and cite their sources.
Background: variants. Although efficacy has been demonstrated in clinical trials, long-term real-world data remain necessary, particularly in mixed groups of treatment-naïve and ERT-switch patients and genotype-phenotype subgroups. Methods: = 39). Demographic, genotypic, biochemical, renal, and cardiac parameters, and clinical outcomes were evaluated. Sex-stratified analyses showed higher LVMI in males than females at baseline, with non-significant reductions in both groups over time. The incidence of non-fatal cardiovascular events was 81 and 43.5 per 1000 person-years in TN and TS groups, respectively. Six male patients (6.9%) experienced adverse events; five discontinued treatment, and one Fabry-related death occurred in the TN group. Conclusion: Migalastat was well tolerated and maintained stable renal and cardiac parameters with plasma lyso-Gb3 improvement. However, a subset of patients showed progression or intolerance, underscoring that variant amenability alone may not predict clinical benefit.
No takes yet. Share an insight, caveat, or question.
McCarron et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: